{"filings":[{"id":649157,"accession_number":"0001453687-26-000087","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-05-26T11:08:51+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027","event_type":"debt","confidence":"high","bullets":["Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.","Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.","CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.","Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.","Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":"2026-05-26","daily_digest_url":"/daily/2026-05-26","daily_digest_rank":5},{"id":92940,"accession_number":"0001453687-26-000081","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.","Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.","Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.","R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).","Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":78000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104188,"accession_number":"0001453687-26-000068","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics board member Murat Kalayoglu resigns effective March 31, 2026","event_type":"leadership","confidence":"high","bullets":["Director Murat Kalayoglu, M.D., Ph.D. resigned from board effective March 31, 2026 to pursue other opportunities.","He served as Chairman of Science and Technology Committee and on Nominating and Corporate Governance Committee.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Kalayoglu had been on board since 2023; no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104187,"accession_number":"0001453687-26-000063","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027","event_type":"other_material","confidence":"high","bullets":["Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.","R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.","Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.","Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.","Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104186,"accession_number":"0001453687-26-000051","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated","event_type":"other_material","confidence":"high","bullets":["Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.","FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.","Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.","Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.","Cash resources expected to fund operations including Phase 3 trial completion through mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120478,"accession_number":"0001453687-25-000140","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","5.05","7.02","7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise","event_type":"leadership","confidence":"high","bullets":["Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.","Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.","Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.","CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.","Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120477,"accession_number":"0001453687-25-000123","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis","event_type":"other_material","confidence":"high","bullets":["100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.","No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.","Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.","Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.","Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120476,"accession_number":"0001453687-25-000119","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.","Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.","Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.","Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.","R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1850000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120475,"accession_number":"0001140361-25-039793","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics Chair Carrie Cox resigns; CEO Carsten Brunn named Chairman, bylaw amended","event_type":"leadership","confidence":"high","bullets":["Carrie Cox resigned from the Board and as Chair on Oct. 29, 2025, to focus on other commitments; not related to any disagreement.","Carsten Brunn, Ph.D., CEO and Board member, appointed Chairman of the Board effective immediately.","Patrick Zenner named Lead Independent Director; Kemal Malik appointed Chairman of the Compensation Committee.","Board approved amended and restated Bylaws to incorporate references to Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120474,"accession_number":"0001453687-25-000106","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025","event_type":"leadership","confidence":"high","bullets":["CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.","Separation agreement signed Oct 20, 2025 provides 12 months salary and pro-rated bonus eligibility.","Dr. Jewell releases all claims against the company in exchange for severance benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120473,"accession_number":"0001453687-25-000104","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.","Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.","Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.","CFO Blaine Davis continues as both principal financial officer and principal accounting officer.","Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137045,"accession_number":"0001453687-25-000098","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.","Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.","R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.","Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1398000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154318,"accession_number":"0001453687-25-000093","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cartesian Therapeutics stockholders elect three Class III directors and approve say-on-pay at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.","Non-binding advisory say-on-pay approved: 19.7M for, 157k against, 2.0M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025 approved: 21.8M for, 6k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154317,"accession_number":"0001453687-25-000091","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics enrolls first patient in Phase 3 AURORA trial of Descartes-08 for myasthenia gravis","event_type":"other_material","confidence":"high","bullets":["First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.","Descartes-08 is administered outpatient without preconditioning chemotherapy; primary endpoint is proportion with MG-ADL improvement ≥3 points at Month 4.","Phase 2b data cited: average 4.8-point MG-ADL reduction at Month 12; in biologic-naive subgroup 7.1-point reduction and 57% minimal symptom expression.","Safety profile consistent with prior data; continues to support outpatient administration without integrating vectors or conditioning chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154316,"accession_number":"0001453687-25-000084","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.","Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.","Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.","Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1100000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154315,"accession_number":"0001453687-25-000077","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026","event_type":"leadership","confidence":"high","bullets":["CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.","Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.","Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.","No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154314,"accession_number":"0001453687-25-000064","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track","event_type":"other_material","confidence":"high","bullets":["Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.","In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.","No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.","Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172901,"accession_number":"0001453687-25-000059","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track","event_type":"earnings","confidence":"high","bullets":["Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.","Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.","Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.","Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172900,"accession_number":"0001453687-25-000054","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics files 8-K with corporate slide deck; no material news evident","event_type":"other_material","confidence":"low","bullets":["Slide deck titled 'Pioneering mRNA Cell Therapy for Autoimmunity' dated March 2025 furnished as Exhibit 99.1.","No financial results, pipeline updates, or guidance changes provided in the filing.","The exhibit is furnished under Regulation FD and contains no new material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}